ArticleInternal medicine (Tokyo, Japan)2026
Changes in the Quantitative Computed Tomography Values in Drug-associated Interstitial Lung Disease Caused by Non-anticancer Drugs.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective A quantitative computed tomography (QCT) analysis based on whole-lung density (WLD) histograms helps monitor the state of interstitial lung disease. We investigated the changes in QCT metrics in patients with drug-associated interstitial lung disease (DILD) and their correlation with inflammatory markers. Methods A QCT analysis using a 3D Slicer software program based on a WLD histogram was performed, excluding patients treated with anticancer agents or those undergoing treatment for malignant tumors to eliminate the effect of tumor size on QCT values. We evaluated the percentages of high attenuation areas (HAA%) at -700 Hounsfield Units (HU) (HAA%-700), -600 HU (HAA%-600), and from -600 to -250 HU [HAA%-(600-250)].Materials We analyzed patients diagnosed with DILD at our hospital between July 2013 and October 2024. Results The HAA%-700, HAA%-600, and HAA%-(600-250) values were significantly higher at diagnosis compared to the post-treatment values (28.14±13.60% versus 15.64±9.70%, p=0.0002; 18.45±10.40% versus 9.88±6.26%, p=0.0002; and 14.00±8.14% versus 7.65±4.72%, p=0.0002, respectively). The steroid-treated group had higher inflammatory marker levels than the non-steroid-treated group at the time of diagnosis. The HAA%-600 was significantly higher in the steroid-treated group than that in the non-steroid-treated group (21.42±12.35% vs. 13.18±4.31%, p=0.0128). The HAA%-700, HAA%-600, and HAA%-(600-250) values correlated with the inflammatory marker values. Conclusion The HAA% values in patients with DILD were significantly higher at diagnosis than after treatment and they also correlated with the inflammatory marker values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.